IGF2 expression and β-catenin levels are increased in Frozen Shoulder Syndrome Abstract Purpose: Frozen Shoulder Syndrome is a brosis of the shoulder joint capsule that is clinically associated with Dupuytren's disease, a brosis of the palmar fascia. Little is known about any commonalities in the pathophysiology of these connective tissue broses. β-catenin, a protein that transactivates gene expression, and levels of IGF2 mRNA, encoding insulin-like growth factor-II, are elevated in Dupuytren's disease. e aim of this study was to determine if correlating changes in β-catenin levels and IGF2 expression are evident in Frozen Shoulder Syndrome.
Frozen Shoulder Syndrome (FSS) is a chronic brotic disorder of the shoulder joint capsule characterized by painful and restricted shoulder motion. is disorder a ects an estimated 2% of adults, is frequently bilateral and can be resistant to therapeutic interventions. Despite its common occurrence, the underlying pathophysiology of this disorder remains ill-de ned [1, 2] . Previous studies have suggested that FSS shares a similar patho-mechanism with Dupuytren's disease (DD) [1] , and that these two connective tissue disorders are clinically associated [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Levels of β-catenin, an established signaling component of the Wnt/frizzled pathway [14] [15] [16] , have been shown to be increased in DD [17] . More recently, expression of IGF2, encoding insulin-like growth factor-II (IGF-II), has been shown to be increased in DD [18] . In this report, β-catenin levels and IGF2 expression were assessed in tissues and cells derived from the rotator cu interval of patients with FSS and Rotator Cu Tear (RCT) to determine if disease-associated changes in these molecules are also evident in FSS and RCT.
Materials and Methods

Tissue collection
Tissue sections were collected with approval of the Human Subjects Research Ethics Board (HSREB) at Western University from surgical specimens of patients undergoing shoulder arthroscopy for the treatment of either FSS or subacromial decompression for RCT. An arthroscopic punch was used to obtain tissue specimens from the rotator cu interval immediately adjacent to the antero-superior arthroscopic portal from patients with FSS and RCT. Representative samples of these tissues were removed at the time of surgery and immediately transported to the laboratory. e tissues were either snap frozen in liquid nitrogen for total protein extraction or processed for primary broblast derivation.
Western immunoblotting
Total protein extracts were prepared from snap frozen tissue using modi ed RIPA bu er. Tissue lysate (25 μg) was subjected to Western blot analysis and β-catenin levels were assessed using an anti-β-catenin monoclonal antibody (clone 14, Transduction Laboratories, Lexington, KY). β-actin levels were assessed in parallel using an anti-β-actin antibody (Sigma, St Louis, MO) to normalize for variability in total protein loading. Antibody speci c bands were visualized using enhanced chemiluminescence (ECL) and Kodak XLS lm. Densitometry analysis was carried out using Scion Image so ware (Scion Corporation, Beta 4.0.2, Frederick, MD). Normalized measurements of β-catenin were plotted as the sample mean (β-catenin /actin) ratio ± standard error of the mean (SEM). Statistical analysis was performed using a paired t-test.
Primary broblast derivation and culture
Primary broblasts were isolated from FSS and RCT tissues using the same techniques as previously described for primary DD broblasts [19] . Cultures were maintained in α-MEMmedium supplemented with 10% fetal bovine serum (FBS, Invitrogen Corporation, Carlsbad, CA) and 1% antibioticantimycotic solution (Sigma-Aldrich, St Louis, MO). All primary broblast cultures were assessed at the lowest passage number achievable up to a maximum of six passages, a er which the cells were discarded. No changes in cell morphology, growth and viability attributable to serial passage were evident in these cells (data not shown).
Real Time PCR
Total RNA samples from primary broblasts were assessed for quality on an Agilent 2100 Bioanalyzer. High quality total RNA (2 µg) was reverse transcribed into cDNA rst strand using the High-Capacity cDNA Archive Kit (Applied Biosystems, city, state) in accordance with the manufacturer's instructions. TaqMan gene expression assays were used to measure IGF2 expression (Hs01005963_m1) relative to the RPLP0 (Hs99999902_m1) as an endogenous control gene. e ΔΔCt method was employed a er con rmation of parallel PCR ampli cation e ciencies of the target and endogenous control on a Real-Time PCR ABI Prism 7500. PCR reactions were carried out under the following conditions: initial denaturation at 95ºC for 5 min followed by cycles of denaturation (95ºC for 15 sec), primer annealing (60ºC for 1 min) and transcript extension (50ºC for 2 min) for 45 cycles.
Results
β-catenin levels are increased in FSS relative to RCT
Western immunoblotting analyses for β-catenin and β-actin immunoreactivity were performed on total protein lysates of FSS and RCT tissues as described in the methods. e majority of samples derived from FSS exhibited increased levels of β-catenin relative to RCT tissues, which mostly expressed very low to undetectable levels of β-catenin, when normalized to β-actin levels as controls. Densitometry analysis con rmed a signi cant di erence in β-catenin levels between FSS and RCT samples (p<0.01, Fig. 1 uantitative (real time) PCR analyses for IGF2 mRNA levels and RPLP0 mRNA levels were performed on total RNA isolated from primary broblasts derived from FSS and RCT tissues as described in the methods. As shown in Fig 2, a signicant (p<0.05) increase in IGF2 mRNA levels was evident in the primary broblasts derived from FSS tissues relative to the primary broblasts derived from RCT tissues when normalized to RPLP0 mRNA levels as controls.
Discussion
Increased β-catenin accumulation [17, 19] and IGF2 expression [18] have been previously identi ed in DD tissue and primary broblasts compared with controls from adjacent, phenotypically non-brotic palmar fascia. As FSS and DD are clinically associated [3, 20] , we were interested to see if these characteristics were common to both connective tissue broses. Our ndings indicate that increased IGF2 expression and β-catenin accumulation are also evident in FSS, supporting the hypothesis that these connective tissue broses share a common pathophysiology.
While β-catenin is best recognised as a component of the Wnt/frizzled signalling pathway, [15, 21] , additional roles for β-catenin in the transforming growth factor (TGF)-β1 [22] [23] [24] and oxidative stress-activated [21] pathways have been described. β-catenin is also an integral component of adherens junctions [15, 25] ; cell-membrane-associated structures that myo broblasts use during cell to cell interactions to promote extra-cellular matrix contraction and remodelling during brosis development [26] . Increased β-catenin levels have been causatively linked to increased broblast proliferation in aggressive bromatosis (desmoid tumor) [27, 28] and hypertrophic scar formation [22] . As these conditions share many molecular similarities with FSS and DD [18, 29] , β-catenin is likely to play analogous broproliferative roles in these diseases. Western immunoblotting also revealed the presence of multiple molecular weight forms of β-catenin in FSS tissues, correlating with similar observations in DD tissues [17] . Whether these ) were subjected to Western immunoblotting and total β-catenin levels were assessed using an anti-β-catenin monoclonal antibody. β-actin levels were assessed to normalize protein loading between samples. Antibody speci c bands were visualized by ECL on Kodak XLS lm. (B) Densitometric analysis of the ECL exposed lm was carried out using Scion Image so ware and normalized measurements of β-catenin were plotted as the sample mean (β-catenin /actin) ratio ± standard error of the mean (SEM). (C) Statistical analysis using a paired t-test (p<0.01).
multiple forms of β-catenin in FSS indicate disease-associated changes in cytoplasmic β-catenin degradation and/or ubiquitination remains to be investigated. IGF2 encodes insulin-like growth factor-II (IGF-II); a peptide growth factor with structural and functional similarities to insulin. In contrast to its well-established roles in promoting cancer growth [30] [31] [32] [33] , relatively little is known about the roles of IGF-II in benign broproliferative diseases like FFS and DD. In addition to DD [18] , IGF2 expression and IGF-II levels are reported to be increased in systemic sclerosisassociated pulmonary brosis [34] . IGF-II can act in combination with TGF-β1 signalling intermediates to promote myobroblast development in vitro [35] and both IGF-II and TGF-β1 can independently induce β-catenin translocation to the nucleus during epithelial mesenchymal transition (EMT) [36] ; a process implicated in both cancer and brosis development [37] [38] [39] . It is possible, therefore, that the increases in IGF2 expression and β-catenin accumulation in FSS may represent components of the same or overlapping signalling pathways.
When assessed from this perspective, IGF-II and β-catenin may have potential as targets for therapeutic interventions to prevent FSS development. Humanized monoclonal antibodies that bind and inactivate the type-I IGF receptor (IGFRI), the primary IGF-II signaling receptor, are currently undergoing clinical trials to prevent IGF-II signaling in cancers [40] [41] [42] .
ese or similar interventions, potentially combined with TGF-β1 signaling suppressors [43] , may have utility for preventing brosis development in FSS, DD and other broproliferative diseases that exhibit increased IGF2 expression and β-catenin accumulation. A detailed understanding of their roles in brosis may also allow us to harness these factors to enhance tissue repair in conditions characterized by a loss of cell proliferation and/or viability, such as rotator cu disease [44, 45] .
Conclusion
is is rst report of increased IGF2 expression and β-catenin accumulation in FSS. ese ndings correlate with our previous reports in DD and support the hypothesis that these connective tissue broses have a common molecular pathophysiology. A greater understanding of these molecular pathways may enhance therapeutic interventions for FSS and may provide further insights into disorders that are characterized by abnormal healing.
